论文部分内容阅读
目的分析耐多药肺结核患者采用3CDLfxPtoZ/9DLfxPtoZ方案治疗的近期临床效果。方法 2002年10月至2005年12月收治的100例耐多药肺结核患者,采用3CDLfxPtoZ/9DLfxPtoZ方案治疗,疗程中进行痰结核分枝杆菌检查和肝功能检查,疗程的3、6、9、12个月摄X线胸片。结果 100例完成疗程时痰菌转阴率88.0%,病灶吸收率94.0%,空洞闭合率88.6%。肝功能异常率12.0%,无1例因药物不良反应停药。结论对耐多药肺结核采用方3CDLfxPtoZ/9DLfxPtoZ方案,近期效果满意,药物不良反应轻微,但其确切效果尚需进一步评价。
Objective To analyze the recent clinical results of 3CDLfxPtoZ / 9DLfxPtoZ regimen in patients with multidrug-resistant pulmonary tuberculosis. Methods A total of 100 MDR-TB patients admitted from October 2002 to December 2005 were treated with 3CDLfxPtoZ / 9DLfxPtoZ regimen. Mycobacterium tuberculosis and liver function tests were performed during the course of treatment. The duration of 3,6,9,12 A month on the X-ray. Results 100 patients completed the treatment of sputum negative conversion rate of 88.0%, 94.0% absorption rate of the cavity, the void closure rate of 88.6%. Abnormal liver function rate of 12.0%, no one due to adverse drug reactions withdrawal. Conclusion The multi-drug-resistant pulmonary tuberculosis with side 3CDLfxPtoZ / 9DLfxPtoZ program, the recent satisfactory results, minor adverse drug reactions, but its exact effect needs further evaluation.